Abstract: The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample.

Abstract: Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2.

Abstract: The invention relates to an antigenic structure that contains a tryptophan epitope, characterised in that said structure is made up of a tryptophan pattern W or a peptide of 3 or 4 amino acids comprising a pattern W, coupled with glutaraldehyde. The invention can he used for screening trypanosomiasis in humans or animals.

Abstract: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), he

Abstract: A microfluidic device and method is provided for handheld diagnostics and assays. The device includes a base having outer surface and a channel therethough for receiving fluid therein. The channel has input and output ports communicating with the outer surface. A lid is also provided. The lid has an outer surface, a first well having a port communicating with the outer surface of the lid, and a second well having a port communicating with the outer surface. The lid moveable between a first disengaged position and a second engaged position wherein the first port of the lid is adjacent the input port of the channel and the second port is adjacent the output port of the channel.

Abstract: The present invention relates to a method of detection of a compound of interest that is present at low levels in a sample. In particular, the present invention relates to a method of detection of a compound of interest in solution by a nucleic acid-labelled binding construct, separation of the unbound nucleic acid-labelled binding construct, and the detection of the bound nucleic acid-labelled binding construct in the solution phase. The present invention is particularly adaptable to be used in conjunction with a nucleic acid amplification reaction for detecting the presence or absence of the nucleic acid portion of binding construct in a sample indicating the presence or absence of the compound of interest.

Abstract: The present invention is directed to methods and devices for detection of cerebrospinal fluid leaks by detection of the CSF protein beta-2 transferrin. The microfluidic devices and methods of the invention combine capture and specific labeling of transferrin from a sample with a subsequent step of isoelectric focusing to separate transferrin isoforms for detection. Microfluidic channels and chambers are patterned on a substrate, designed so that on one region (i.e., a microfluidic channel or chamber) of the substrate transferrin is selectively captured from the sample and labeled, and in a second region of the substrate, transferrin isoforms are separated using isoelectric focusing. Detection of two transferrin bands, indicating the presence of beta-2-transferrin, indicates the presence of CSF in the sample. The devices and methods of the invention provide a safe, efficient, and ultrarapid modality with high specificity and sensitivity for the detection of CSF in the acute care setting.

Abstract: The use of the IRAP protein for implementing methods of diagnosis and of prognosis.

Abstract: Disclosed is a method for preparing a composition enriched for receptors (typically molecular impringet polymers, MIPs) that bind an agent, where said receptors each specifically bind at least two discrete sites on said agent, by subjecting a sample of receptors to a first step of affinity purification with the agent where one binding site on the agent is non-accessible for binding to the receptors and subsequently subjecting the purified receptors to at least one further step of affinity purification with the agent where a second binding site on the agent is non-accessible.

Abstract: An optical glucose sensor comprising: a sensing region comprising a boronic acid receptor for binding to glucose and a fluorophore associated with said receptor; an optical waveguide for directing incident light onto the sensing region; and a hydrophilic, polymeric, glucose-permeable barrier layer which is provided on at least a part of the sensing region; wherein the sensor is adapted so that glucose enters the sensing region of the sensor through said barrier layer.

Abstract: A disease detection system which includes an electrophoresis apparatus and a biomarker detector. The apparatus includes: (a) a transport passage; (b) a plurality of separation passages, each of the separation passages having an overlapping portion that overlaps the transport passage; and (c) a different biomarker concentrator in each of the overlapping portions and which concentrates at least one different biomarker from a specimen from an animal introduced into the transport passage. A plurality of the different biomarkers is associated with at least one predetermined disease, such as diabetes, heart disease or cancer. The detector detects the presence of the different biomarkers which were concentrated by the biomarker concentrators and delivered to the biomarker detector via the separation passages. First and second sets of the biomarker concentrators can be associated with respective first and second predetermined diseases and the user can determine which set will be used in each procedure.

Abstract: The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample.

Abstract: The present invention provides methods of making polymer-based biosensors and the biosensors made by said methods, wherein the biosensors comprise conducting polymers and negatively charged nanoparticles comprising a capture moiety. The present invention also provides methods of detecting analytes in a solution by contacting the solution with said polymer-based biosensors.

Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.

Abstract: Embodiments of the present invention are directed to improved methods and devices for analyzing a cell, aggregated cells, or a solid tumor. Such methods and devices are, for example, useful in the field of pathology and can provide improved cell processing and analytical results.

Abstract: The invention intends to provide a bioassay method using a simple in-vitro test for Daikinchuto, and further to provide a more highly accurate method for quality control of Daikenchuto using the same. These methods are a bioassay method for the pharmacological activity of Daikenchuto, characterized in that a test sample containing Daikenchuto is added to cultured serotonin-producing cells, and the serotonin content in the culture supernatant is subsequently measured; and a quality control method for Daikenchuto preparations in which the pharmacological activity of a test preparation and a reference preparation for which the pharmacological effect as Daikenchuto has been clinically confirmed are evaluated under the same conditions, and the equivalence of the reference preparation and testing preparation is evaluated.

Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.

Abstract: Provided is a method of separating cellular components, the method including: a) contacting a guest compound-bound reactive compound with cells; b) lysing the cells; c) adding a host compound-bound solid phase to a solution including the lysates of the cells to prepare a mixture; d) separating binding pairs of the guest compound bound to cellular components and the host compound bound to the solid phase from the mixture, and purifying the binding pairs; and e) separating the cellular components from the binding pairs, wherein the guest compound-bound reactive compound is obtained through a covalent bond between a reactive compound and a guest compound represented by Formula 2 below guest, the host compound-bound solid phase is obtained through a covalent bond between a solid phase and a host compound represented by Formula 1 below, and the reactive compound includes at least one selected from the group consisting of a biomolecule, N-hydroxysuccimide, an antigen, an antibody, an aptamer, folic acid, transferri

Abstract: [Problems] An object of the present invention is to provide a novel method which can expand the measurement range in an immunoassay method. [Means for Solution] The immunoassay method according to the present invention comprises allowing a polyoxyethylene alkyl ether sulfate and a polyoxyethylene sorbitan fatty acid ester to coexist in a reaction system. [Effects] According to the method of the present invention, variation (standard deviation) in blank measurement values in particular can be reduced, so that measurement values are stabilized. By this, a significant difference can be obtained in measurement values even in a low-concentration range where conventional immunoassay methods have difficulty in performing measurements; therefore, the measurement accuracy in such low-concentration range can be improved.

Abstract: The present invention relates to a separation matrix comprised of a porous or non-porous support to which ligands have been immobilized, wherein said ligands comprise at least one aliphatic sulfamide. The invention also relates to a chromatography column that contains the described separation matrix, as well as to a method of isolating immunoglobulins, such as IgG, Fab fragments, fusion proteins containing immunoglobulins etc, by adsorption to a separation matrix that comprises the aliphatic sulfamide ligands of the invention.